Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Medtronic
Dow
Moodys
Baxter
Johnson and Johnson
Mallinckrodt

Last Updated: January 23, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Faldaprevir

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the development status for investigational drug Faldaprevir?

Faldaprevir is an investigational drug.

There have been 23 clinical trials for Faldaprevir. The most recent clinical trial was a Phase 3 trial, which was initiated on May 1st 2013.

The most common disease conditions in clinical trials are Hepatitis C, Hepatitis, and Hepatitis C, Chronic. The leading clinical trial sponsors are Boehringer Ingelheim, Trek Therapeutics, PBC, and Hospital Universitario Puerta del Mar.

There are twenty-three US patents protecting this investigational drug and three hundred and forty-two international patents.

Recent Clinical Trials for Faldaprevir
TitleSponsorPhase
A Study of Faldaprevir, TD-6450 and Other Antivirals in Participants With Genotype 1b Hepatitis C Virus InfectionTrek Therapeutics, PBCPhase 2
A Study of Faldaprevir, Ribavirin and TD-6450 in Participants With Genotype 4 Hepatitis C Virus InfectionTrek Therapeutics, PBCPhase 2
A Study to Investigate the Phototoxic Potential of FaldaprevirBoehringer IngelheimPhase 1

See all Faldaprevir clinical trials

Clinical Trial Summary for Faldaprevir

Top disease conditions for Faldaprevir
Top clinical trial sponsors for Faldaprevir

See all Faldaprevir clinical trials

US Patents for Faldaprevir

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Faldaprevir   Start Trial Hepatitis C inhibitor compounds Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE)   Start Trial
Faldaprevir   Start Trial Hepatitis C inhibitor compounds Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE)   Start Trial
Faldaprevir   Start Trial Crystalline forms of a potent HCV inhibitor Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE)   Start Trial
Faldaprevir   Start Trial Crystalline forms of a potent HCV inhibitor Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE)   Start Trial
Faldaprevir   Start Trial Combination therapy for treating HCV infection Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Faldaprevir

Drugname Country Document Number Estimated Expiration Related US Patent
Faldaprevir Austria 378334 2023-05-21   Start Trial
Faldaprevir Australia 2004240704 2023-05-21   Start Trial
Faldaprevir Brazil PI0410456 2023-05-21   Start Trial
Faldaprevir Canada 2522577 2023-05-21   Start Trial
Faldaprevir Chile 2004001161 2023-05-21   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Harvard Business School
Baxter
Medtronic
AstraZeneca
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.